Opinion

Video

Implications of Real-World Data in the 1L Treatment of High-Risk CLL

Catherine C. Coombs, MD, discusses the value of real-world data in informing the treatment of patients with chronic lymphocytic leukemia.

Video content above is prompted by the following question(s):

  • Please outline your general treatment strategy for patients with high-risk CLL. How do recently presented real-world data influence your treatment approach?
Related Videos
A panel of 3 experts on CLL
Video 4 - 2 KOLs are featured in, "Clinical Decision Making to Overcome Treatment Resistance in 2L HR+ HER2- mBC"
Video 2 - 2 KOLs are featured in, "Mechanisms of Resistance after 1L CDK4/6i + ET: The PI3K/AKT/PTEN Pathway"
2 KOLs are featured in this series
2 KOLs are featured in this series
Alexey Danilov, MD, PhD
5 KOLs are featured in this panel.
5 KOLs are featured in this panel.
Paolo Ghia, MD, PhD
2 KOLs are featured in this panel.